Apolipoprotein E4 (ApoE4) is a major genetic risk factor for Alzheimer’s disease (AD). The E4 allele of ApoE plays a crucial role in the inflammatory and neurodegenerative processes associated with AD. This is evident from the multiple effects of the ApoE isoforms in amyloid-β (Aβ) aggregation. Glia maturation factor (GMF) is a brain-specific neuroinflammatory protein that we have previously demonstrated to be significantly upregulated in various regions of AD brains compared to non-AD control brains and that it induces neurodegeneration. We have previously reported that GMF is predominantly expressed in the reactive astrocytes surrounding amyloid plaques (APs) in AD brain. In the present study, using immunohistochemical and dual immunofluorescence staining, we show the expression and colocalization of GMF and ApoE4 in AD brains. Our results show that ApoE4 is present within the APs of AD brain. Further, we found that GMF and ApoE4 were strongly expressed and co-associated in APs and in the reactive astrocytes surrounding APs in AD. An increased expression of GMF in APs and neurofibrillary tangles in the AD brain, and the co-localization of GMF and ApoE4 in APs suggest that GMF and ApoE4 together should be contributing to the neuropathological changes associated with AD.
NelsonPT, AbnerEL, SchmittFA, KryscioRJ, JichaGA, SantacruzK, SmithCD, PatelE, MarkesberyWR (2009) Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol68, 774–784.
4.
NelsonPT, DimayugaJ, WilfredBR (2010) MicroRNA in situ hybridization in the human entorhinal and transentorhinal cortex. Front Hum Neurosci4, 7.
5.
ZaheerS, ThangavelR, WuY, KhanMM, KempurajD, ZaheerA (2013) Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer’s disease mice. Neurochem Res38, 218–225.
StolmeierD, ThangavelR, AnantharamP, KhanMM, KempurajD, ZaheerA (2013) Glia maturation factor expression in hippocampus of human Alzheimer’s disease. Neurochem Res38, 1580–1589.
8.
BraakH, AlafuzoffI, ArzbergerT, KretzschmarH, Del TrediciK (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol112, 389–404.
9.
FuhrerTE, PalpagamaTH, WaldvogelHJ, SynekBJL, TurnerC, FaullRL, KwakowskyA (2017) Impaired expression of GABA transporters in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus. Neuroscience351, 108–118.
10.
LlorensF, ThuneK, Andres-BenitoP, TahirW, AnsoleagaB, Hernandez-OrtegaK, MartiE, ZerrI, FerrerI (2017) MicroRNA expression in the locus coeruleus, entorhinal cortex, and hippocampus at early and middle stages of Braak neurofibrillary tangle pathology. J Mol Neurosci63, 206–215.
11.
Van HoesenGW, HymanBT (1990) Hippocampal formation: Anatomy and the patterns of pathology in Alzheimer’s disease. Prog Brain Res83, 445–457.
12.
Van HoesenGW, HymanBT, DamasioAR (1991) Entorhinal cortex pathology in Alzheimer’s disease. Hippocampus1, 1–8.
13.
Martinez-MorilloE, HanssonO, AtagiY, BuG, MinthonL, DiamandisEP, NielsenHM (2014) Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls. Acta Neuropathol127, 633–643.
14.
PremkumarDR, CohenDL, HederaP, FriedlandRP, KalariaRN (1996) Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am J Pathol148, 2083–2095.
15.
LiuM, KuhelDG, ShenL, HuiDY, WoodsSC (2012) Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am J Physiol Regul Integr Comp Physiol303, R903–R908.
16.
GlocknerF, MeskeV, OhmTG (2002) Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer’s disease. Neuroscience114, 1103–1114.
17.
SaundersAM, StrittmatterWJ, SchmechelD, George-HyslopPH, Pericak-VanceMA, JooSH, RosiBL, GusellaJF, Crapper-MacLachlanDR, AlbertsMJ, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology43, 1467–1472.
18.
StrittmatterWJ, SaundersAM, SchmechelD, Pericak-VanceM, EnghildJ, SalvesenGS, RosesAD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A90, 1977–1981.
19.
AroldS, SullivanP, BilousovaT, TengE, MillerCA, PoonWW, VintersHV, CornwellLB, SaingT, ColeGM, GylysKH (2012) Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer’s disease and apoE TR mouse cortex. Acta Neuropathol123, 39–52.
20.
ThangavelR, SahuSK, Van HoesenGW, ZaheerA (2008) Modular and laminar pathology of Brodmann’s area 37 in Alzheimer’s disease. Neuroscience152, 50–55.
21.
ThangavelR, SahuSK, Van HoesenGW, ZaheerA (2009) Loss of nonphosphorylated neurofilament immunoreactivity in temporal cortical areas in Alzheimer’s disease. Neuroscience160, 427–433.
22.
PurushothumanS, JohnstoneDM, NandasenaC, MitrofanisJ, StoneJ (2014) Photobiomodulation with near infrared light mitigates Alzheimer’s disease-related pathology in cerebral cortex - evidence from two transgenic mouse models. Alzheimers Res Ther6, 2.
23.
MahleyRW, WeisgraberKH, HuangY (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A103, 5644–5651.
24.
ArendtT, SchindlerC, BrucknerMK, EschrichK, BiglV, ZedlickD, MarcovaL (1997) Plastic neuronal remodeling is impaired in patients with Alzheimer’s disease carrying apolipoprotein epsilon 4 allele. J Neurosci17, 516–529.
25.
StrittmatterWJ, WeisgraberKH, HuangDY, DongLM, SalvesenGS, Pericak-VanceM, SchmechelD, SaundersAM, GoldgaberD, RosesAD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A90, 8098–8102.
26.
WisniewskiT, GolabekA, MatsubaraE, GhisoJ, FrangioneB (1993) Apolipoprotein E: Binding to soluble Alzheimer’s beta-amyloid. Biochem Biophys Res Commun192, 359–365.
27.
HuangYA, ZhouB, WernigM, SudhofTC (2017) ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Abeta secretion. Cell168, 427–441e421.
28.
RebeckGW, ReiterJS, StricklandDK, HymanBT (1993) Apolipoprotein E in sporadic Alzheimer’s disease: Allelic variation and receptor interactions. Neuron11, 575–580.
29.
ThangavelR, StolmeierD, YangX, AnantharamP, ZaheerA (2012) Expression of glia maturation factor in neuropathological lesions of Alzheimer’s disease. Neuropathol Appl Neurobiol38, 572–581.
30.
ZaheerA, LimR (1997) Protein kinase A (PKA)- and protein kinase C-phosphorylated glia maturation factor promotes the catalytic activity of PKA. J Biol Chem272, 5183–5186.
ZaheerA, MathurSN, LimR (2002) Overexpression of glia maturation factor in astrocytes leads to immune activation of microglia through secretion of granulocyte-macrophage-colony stimulating factor. Biochem Biophys Res Commun294, 238–244.
33.
TarkowskiE, WallinA, ReglandB, BlennowK, TarkowskiA (2001) Local and systemic GM-CSF increase in Alzheimer’s disease and vascular dementia. Acta Neurol Scand103, 166–174.
34.
GardenGA, MollerT (2006) Microglia biology in health and disease. J Neuroimmune Pharmacol1, 127–137.
